Skip to main content
Top
Published in: Current Rheumatology Reports 3/2010

01-06-2010

Drug-related Myopathies of Which the Clinician Should Be Aware

Authors: Ritu Valiyil, Lisa Christopher-Stine

Published in: Current Rheumatology Reports | Issue 3/2010

Login to get access

Abstract

Many drugs used for therapeutic interventions can cause unanticipated toxicity in muscle tissue, often leading to considerable morbidity. A drug-induced, or toxic, myopathy is defined as the acute or subacute manifestation of myopathic symptoms such as muscle weakness, myalgia, creatine kinase elevation, or myoglobinuria that can occur in patients without muscle disease when they are exposed to certain drugs. A brief review of agents with a known association with myotoxicity and the proposed mechanisms linked to that toxicity is outlined; however, the purpose of this review is to highlight recent discoveries and advances in the field of toxic myopathies that have practical implications for practicing physicians. Because many drug-related myopathies are potentially reversible at early stages, it is important for clinicians to recognize toxic myopathies early in their course to determine when to discontinue therapy and potentially prevent irreversible muscle damage.
Literature
1.
4.
go back to reference Jacobson TA: Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008, 83:687–700.CrossRefPubMed Jacobson TA: Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008, 83:687–700.CrossRefPubMed
5.
go back to reference • Joy TR, Hegele RA: Narrative review: statin-related myopathy. Ann Intern Med 2009, 150:858–868. This is a nice comprehensive overview of statin myopathy to date.PubMed • Joy TR, Hegele RA: Narrative review: statin-related myopathy. Ann Intern Med 2009, 150:858–868. This is a nice comprehensive overview of statin myopathy to date.PubMed
6.
go back to reference • MRC/BHF Heart Protection Study Collaborative Group; Armitage J, Bowman L, Collins R, et al.: Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin Pharmacol 2009, 9:6. This is one of the most comprehensive long-term, placebo-controlled trials undertaken to assess muscle and liver toxicity in patients at high risk for cardiovascular events.CrossRefPubMed • MRC/BHF Heart Protection Study Collaborative Group; Armitage J, Bowman L, Collins R, et al.: Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin Pharmacol 2009, 9:6. This is one of the most comprehensive long-term, placebo-controlled trials undertaken to assess muscle and liver toxicity in patients at high risk for cardiovascular events.CrossRefPubMed
8.
go back to reference Bays H. Statin safety: an overview and assessment of the data—2005. Am J Cardiol 2006, 97:6C–26C.CrossRefPubMed Bays H. Statin safety: an overview and assessment of the data—2005. Am J Cardiol 2006, 97:6C–26C.CrossRefPubMed
9.
go back to reference Thompson PD, Clarkson PM, Rosenson RS; National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel: An assessment of statin safety by muscle experts. Am J Cardiol 2006, 97:69C–76C.CrossRefPubMed Thompson PD, Clarkson PM, Rosenson RS; National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel: An assessment of statin safety by muscle experts. Am J Cardiol 2006, 97:69C–76C.CrossRefPubMed
10.
go back to reference Mosshammer D, Lorenz G, Meznaric S, et al.: Statin use and its association with musculoskeletal symptoms—a cross-sectional study in primary care settings. Fam Pract 2009, 26:88–95.CrossRefPubMed Mosshammer D, Lorenz G, Meznaric S, et al.: Statin use and its association with musculoskeletal symptoms—a cross-sectional study in primary care settings. Fam Pract 2009, 26:88–95.CrossRefPubMed
11.
go back to reference Jacobson TA: Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006, 97:44C–51C.CrossRefPubMed Jacobson TA: Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006, 97:44C–51C.CrossRefPubMed
12.
go back to reference Davidson MH, Clark JA, Glass LM, Kanumalla A: Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol 2006, 97:32C–43C.CrossRefPubMed Davidson MH, Clark JA, Glass LM, Kanumalla A: Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol 2006, 97:32C–43C.CrossRefPubMed
13.
go back to reference •• SEARCH Collaborative Group; Link E, Parish S, Armitage J, et al.: SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 2008, 359:789–799. This was a well-designed study with robust data for proof of principle of genetic susceptibility as a potential cause of statin myopathy.CrossRefPubMed •• SEARCH Collaborative Group; Link E, Parish S, Armitage J, et al.: SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 2008, 359:789–799. This was a well-designed study with robust data for proof of principle of genetic susceptibility as a potential cause of statin myopathy.CrossRefPubMed
14.
go back to reference • Voora D, Shah SH, Spasojevic I, et al.: The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609–1616. A sister study to that by the SEARCH Collaborative Group [13••], this study eloquently expanded previous SNP association findings to suggest not only bona fide statin myopathy, but also that patients with myalgias with normal CK can also have a genetic predisposition that may be statin specific rather than a class effect.CrossRefPubMed • Voora D, Shah SH, Spasojevic I, et al.: The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009, 54:1609–1616. A sister study to that by the SEARCH Collaborative Group [13••], this study eloquently expanded previous SNP association findings to suggest not only bona fide statin myopathy, but also that patients with myalgias with normal CK can also have a genetic predisposition that may be statin specific rather than a class effect.CrossRefPubMed
15.
go back to reference Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002, 106:1024–1028.CrossRefPubMed Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002, 106:1024–1028.CrossRefPubMed
16.
go back to reference Bruckert E, Hayem G, Dejager S, et al.: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403–414.CrossRefPubMed Bruckert E, Hayem G, Dejager S, et al.: Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403–414.CrossRefPubMed
17.
go back to reference Supala-Berger A, Fine E, Heffner R, Young-McLain E: Hyaline inclusion myopathy: unmasked by statin therapy. Muscle Nerve 2009, 40:657–661.CrossRefPubMed Supala-Berger A, Fine E, Heffner R, Young-McLain E: Hyaline inclusion myopathy: unmasked by statin therapy. Muscle Nerve 2009, 40:657–661.CrossRefPubMed
18.
go back to reference Phillips PS, Haas RH, Bannykh S, et al.; Scripps Mercy Clinical Research Center: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137:581–585.PubMed Phillips PS, Haas RH, Bannykh S, et al.; Scripps Mercy Clinical Research Center: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137:581–585.PubMed
19.
go back to reference Mohaupt MG, Karas RH, Babiychuk EB, et al.: Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009, 181:E11–E18.PubMed Mohaupt MG, Karas RH, Babiychuk EB, et al.: Association between statin-associated myopathy and skeletal muscle damage. CMAJ 2009, 181:E11–E18.PubMed
20.
go back to reference Wu AH, Smith A, Wians F: Interpretation of creatine kinase and aldolase for statin-induced myopathy: reliance on serial testing based on biological variation. Clin Chim Acta 2009, 399:109–111.CrossRefPubMed Wu AH, Smith A, Wians F: Interpretation of creatine kinase and aldolase for statin-induced myopathy: reliance on serial testing based on biological variation. Clin Chim Acta 2009, 399:109–111.CrossRefPubMed
21.
go back to reference • Backes JM, Venero CV, Gibson CA, et al.: Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008, 42:341–346. This alternative dosing strategy offers an alternative dosing schedule for statin-intolerant patients.CrossRefPubMed • Backes JM, Venero CV, Gibson CA, et al.: Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008, 42:341–346. This alternative dosing strategy offers an alternative dosing schedule for statin-intolerant patients.CrossRefPubMed
22.
go back to reference • Ruisinger JF, Backes JM, Gibson CA, Moriarty PM: Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol 2009, 103:393–394. Like that by Backes et al. [21•], this study provided some data to suggest tolerability and efficacy for alternative statin dosing scheduled in statin-intolerant patients. This study noted a 17% reduction in total cholesterol, a 23% reduction in low-density lipoprotein cholesterol, a 12% reduction in triglycerides, and a 5% increase in high-density lipoprotein cholesterol (all P < 0.001) during a mean follow-up of 4 ± 2 months.CrossRefPubMed • Ruisinger JF, Backes JM, Gibson CA, Moriarty PM: Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance. Am J Cardiol 2009, 103:393–394. Like that by Backes et al. [21•], this study provided some data to suggest tolerability and efficacy for alternative statin dosing scheduled in statin-intolerant patients. This study noted a 17% reduction in total cholesterol, a 23% reduction in low-density lipoprotein cholesterol, a 12% reduction in triglycerides, and a 5% increase in high-density lipoprotein cholesterol (all P < 0.001) during a mean follow-up of 4 ± 2 months.CrossRefPubMed
23.
go back to reference Glueck CJ, Rawal B, Khan NA, et al.: Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia? Metabolism 2009, 58:233–238.CrossRefPubMed Glueck CJ, Rawal B, Khan NA, et al.: Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia? Metabolism 2009, 58:233–238.CrossRefPubMed
24.
go back to reference ACCORD Study Group; Buse JB, Bigger JT, Byington RP, et al.: Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007, 99:21i–33i.CrossRefPubMed ACCORD Study Group; Buse JB, Bigger JT, Byington RP, et al.: Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007, 99:21i–33i.CrossRefPubMed
26.
27.
go back to reference Rowan C, Brinker AD, Nourjah P, et al.: Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf 2009, 18:301–309.CrossRefPubMed Rowan C, Brinker AD, Nourjah P, et al.: Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors. Pharmacoepidemiol Drug Saf 2009, 18:301–309.CrossRefPubMed
28.
go back to reference • Grable-Esposito P, Katzberg HD, Greenberg SA, et al.: Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41:185–190. This study demonstrated a robust association between a presumed necrotizing myopathy and statin exposure.PubMed • Grable-Esposito P, Katzberg HD, Greenberg SA, et al.: Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010, 41:185–190. This study demonstrated a robust association between a presumed necrotizing myopathy and statin exposure.PubMed
29.
go back to reference • Christopher-Stine L, Casciola-Rosen L, Hong G, et al.: A novel autoantibody recognizing 200 and100 kDa proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010 (in press). This study, along with that by Grable-Esposito et al. [28•], shows that patients with statin exposure may go on to develop an immune-mediated myopathy—often a necrotizing myopathy. • Christopher-Stine L, Casciola-Rosen L, Hong G, et al.: A novel autoantibody recognizing 200 and100 kDa proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010 (in press). This study, along with that by Grable-Esposito et al. [28•], shows that patients with statin exposure may go on to develop an immune-mediated myopathy—often a necrotizing myopathy.
30.
go back to reference Blanco-Colio LM, Villa A, Ortego M, et al.: 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002, 161:17–26.CrossRefPubMed Blanco-Colio LM, Villa A, Ortego M, et al.: 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002, 161:17–26.CrossRefPubMed
32.
go back to reference Becker DJ, Gordon RY, Halbert SC, et al.: Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009, 150:830–839, W147–W149.PubMed Becker DJ, Gordon RY, Halbert SC, et al.: Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 2009, 150:830–839, W147–W149.PubMed
33.
go back to reference Lapi F, Gallo E, Bernasconi S, et al.: Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian surveillance system of natural health products. Br J Clin Pharmacol 2008, 66:572–574.CrossRefPubMed Lapi F, Gallo E, Bernasconi S, et al.: Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian surveillance system of natural health products. Br J Clin Pharmacol 2008, 66:572–574.CrossRefPubMed
34.
go back to reference Halbert SC, French B, Gordon RY, et al.: Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010, 105:198–204.CrossRefPubMed Halbert SC, French B, Gordon RY, et al.: Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010, 105:198–204.CrossRefPubMed
35.
go back to reference Florentin M, Liberopoulos EN, Elisaf MS: Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008, 62:88–96.CrossRefPubMed Florentin M, Liberopoulos EN, Elisaf MS: Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008, 62:88–96.CrossRefPubMed
36.
go back to reference Dalakas MC, Illa I, Pezeshkpour GH, et al.: Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990, 322:1098–1105.PubMedCrossRef Dalakas MC, Illa I, Pezeshkpour GH, et al.: Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990, 322:1098–1105.PubMedCrossRef
37.
go back to reference Danta G, Hilton RC, Lynch PG: Chronic progressive external ophthalmoplegia. Brain 1975, 98:473–492.CrossRefPubMed Danta G, Hilton RC, Lynch PG: Chronic progressive external ophthalmoplegia. Brain 1975, 98:473–492.CrossRefPubMed
38.
go back to reference Pfeffer G, Côté HC, Montaner JS, et al.: Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. Neurology 2009, 73:71–72.CrossRefPubMed Pfeffer G, Côté HC, Montaner JS, et al.: Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy. Neurology 2009, 73:71–72.CrossRefPubMed
39.
go back to reference Somani AK, Swick AR, Cooper KD, McCormick TS: Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 2008, 144:1341–1349.CrossRefPubMed Somani AK, Swick AR, Cooper KD, McCormick TS: Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 2008, 144:1341–1349.CrossRefPubMed
40.
go back to reference Seok JI, Lee DK, Lee CH, et al.: Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009, 49:2080–2086.CrossRefPubMed Seok JI, Lee DK, Lee CH, et al.: Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology 2009, 49:2080–2086.CrossRefPubMed
41.
go back to reference Casado E, Gratacós J, Tolosa C, et al.: Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis 2006, 65:385–390.CrossRefPubMed Casado E, Gratacós J, Tolosa C, et al.: Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis 2006, 65:385–390.CrossRefPubMed
42.
go back to reference Kalajian AH, Callen JP: Myopathy induced by antimalarial agents: the relevance of screening muscle enzyme levels. Arch Dermatol 2009, 145:597–600.CrossRefPubMed Kalajian AH, Callen JP: Myopathy induced by antimalarial agents: the relevance of screening muscle enzyme levels. Arch Dermatol 2009, 145:597–600.CrossRefPubMed
43.
go back to reference Covar RA, Leung DY, McCormick D, et al.: Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000, 106:651–659.CrossRefPubMed Covar RA, Leung DY, McCormick D, et al.: Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000, 106:651–659.CrossRefPubMed
44.
go back to reference Bowyer SL, LaMothe MP, Hollister JR: Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 1985, 76:234–242.CrossRefPubMed Bowyer SL, LaMothe MP, Hollister JR: Steroid myopathy: incidence and detection in a population with asthma. J Allergy Clin Immunol 1985, 76:234–242.CrossRefPubMed
45.
go back to reference • Dirks-Naylor AJ, Griffiths CL: Glucocorticoid-induced apoptosis and cellular mechanisms of myopathy. J Steroid Biochem Mol Biol 2009, 117:1–7. This is an intriguing and novel concept to help elucidate the mechanism of glucocorticoid-related myopathy.CrossRefPubMed • Dirks-Naylor AJ, Griffiths CL: Glucocorticoid-induced apoptosis and cellular mechanisms of myopathy. J Steroid Biochem Mol Biol 2009, 117:1–7. This is an intriguing and novel concept to help elucidate the mechanism of glucocorticoid-related myopathy.CrossRefPubMed
46.
go back to reference Ochi S, Taniguchi K, Nagashima M: Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. Mod Rheumatol 2009, 19:443–446.CrossRefPubMed Ochi S, Taniguchi K, Nagashima M: Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. Mod Rheumatol 2009, 19:443–446.CrossRefPubMed
47.
go back to reference Hinojosa J, Borrás-Blasco J, Maroto N, et al.: Severe myalgia associated with adalimumab treatment in a patient with Crohn’s disease. Ann Pharmacother 2008, 42:1130–1133.CrossRefPubMed Hinojosa J, Borrás-Blasco J, Maroto N, et al.: Severe myalgia associated with adalimumab treatment in a patient with Crohn’s disease. Ann Pharmacother 2008, 42:1130–1133.CrossRefPubMed
48.
go back to reference Shanmugam VK, Matsumoto C, Pien E, et al.: Voriconazole-associated myositis. J Clin Rheumatol 2009, 15:350–353.CrossRefPubMed Shanmugam VK, Matsumoto C, Pien E, et al.: Voriconazole-associated myositis. J Clin Rheumatol 2009, 15:350–353.CrossRefPubMed
Metadata
Title
Drug-related Myopathies of Which the Clinician Should Be Aware
Authors
Ritu Valiyil
Lisa Christopher-Stine
Publication date
01-06-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 3/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0104-3

Other articles of this Issue 3/2010

Current Rheumatology Reports 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.